Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion

Haematologica

Volumn 93, Issue 1, 2008, Pages 49-56

  Lahortiga, Idoya ^a,b   Akin, Cem ^c   Cools, Jan ^a,b   Wilson, Todd M ^d   Mentens, Nicole ^a,b   Arthur, Diane C ^e   Maric, Irina ^f   Noel, Pierre ^a   Kocabas, Can ^d   Marynen, Peter ^b   Lessin, Lawrence S ^g   Wlodarska, Iwona ^b   Robyn, Jamie ^d   Metcalfe, Dean D ^d  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Chronic basophilic leukemia; Imatinib; PRKG2 PDGFRB; Systemic mastocytosis

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADULT; ANIMAL CELL; ARTICLE; BASOPHILIA; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DOCUMENTATION; DRUG ACTIVITY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENETIC TRANSFORMATION; HUMAN; MALE; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PRKG2 GENE; PROTEIN DOMAIN; SYSTEMIC MASTOCYTOSIS;

ANIMALS; BONE MARROW; CYTOGENETICS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MASTOCYTOSIS, SYSTEMIC; MICE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 38549089581     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11836     Document Type: Article

References (25)

1. Robyn J, Metcalfe DD. Systemic mastocytosis. Adv Immunol 2006;89:169-243.
2. Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005;46:35-48.
3. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004;57:604-8.
4. Pullarkat VA, Bueso-Ramos C, Lai R, Kroft S, Wilson CS, Pullarkat ST, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73:12-7.
5. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005; 90:949-68.
6. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
7. Lierman E, Cools J. ETV6 and PDGFRB: a license to fuse. Haematologica 2007;92:145-7.
8. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates ana activates PDGFbetaR kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996;93:14845-50.
9. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFR-alpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006;103:8078-83.
10. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graerf A, Fabarius A, Hagen V, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 2007;92:163-9.
11. Shaffer LG, Tommerup N (eds). ISCN (2005): An International System for Human Cytogenetic Nomenclature; S. Karger, Basel 2005.
12. De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005; 105:4849-52.
13. Kyle RA, Pease GL. Basophilic leukemia. Arch Intern Med 1966; 118:205-10.
14. Pardanani AD, Morice WG, Hoyer JD, Tefferi A. Chronic basophilic leukemia: a distinct clinico-pathologic entity? Eur J Haematol 2003;71:18-22.
15. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-92.
16. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99: 1741-4.
17. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103:3222-5.
18. Dalal BI, Horsman DE, Bruyere H, Forrest DL. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation. Am J Hematol 2007; 82:77-9.
19. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-6.
20. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
21. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6.
22. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-6.
23. He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, Choi JK, et al. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 2002;99:2957-68.
24. Xiao S, McCarthy JG, Aster JC, Fletcher JA. ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain. Blood 2000;96:699-704.
25. Hubbard SR. Juxtamembrane auto-inhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:464-71.